Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
|Articles|August 15, 2013
Not a Risk Factor for Clostridium difficile Infection?
Previous antibiotic use and hospitalization are well known risk factors for C difficile infection. Are age, PPI use, immunosuppression, and BMI all also risk factors?
Advertisement
Previous antibiotic use and hospitalization are well known risk factors for the development of Clostridium difficile infection. All of the following are additional risk factors except which one?
A. Age
B. PPI use
C. Immunosuppression
D. BMI
Advertisement
Related to this article
A new scientific statement calls for a shift in obesity management and treatment to focus on overall health improvements rather than just weight loss alone.
New research underscores the need for public health interventions to improve the microbial and fiber content of diets in the US.
Semaglutide brought 40.4% of children below the obesity BMI threshold, according to top-line results from the phase 3 STEP Young clinical trial.
US clinicians increasingly prescribe GLP-1 drugs to young children with obesity, although overall use remains limited and access disparities persist.
FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.
A Vaccine Integrity Project review found influenza, COVID-19, and RSV immunizations continue to protect against severe illness, hospitalization, and death.
FDA approved bictegravir/lenacapavir for adults with suppressed HIV-1 and no known or suspected component resistance.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Approves Sotatercept-csrk Label Update for Newly Diagnosed PAH
2
Endocrine Society Obesity Statement Calls for Goals Beyond Weight Loss
3
Lumateperone Reduces Acute Mania Symptoms in Phase 3 Bipolar I Trial
4
Clinical Inertia and Poor Measurement Technique Undermine BP Control
5